이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

장기간 지속된 궤양성 대장염에서 결장암 위험을 낮추기 위한 아토르바스타틴 테스트

2026년 11월 17일 업데이트: Northwestern University

장기간 지속된 궤양성 대장염 관련 암의 위험을 줄이기 위해 아토르바스타틴에 의한 우성-음성 미스센스 돌연변이 P53을 표적으로 하는 무작위 및 위약 대조 2상 시험

This phase II trial studies the effect of atorvastatin in treating patients with ulcerative colitis who have a dominant-negative missense P53 mutation and are at risk of developing large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk of developing large intestinal cancer. Better ways to control ulcerative colitis and more knowledge about how to prevent colon cancer are needed. Atorvastatin is a drug used to lower the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest pain). It blocks an enzyme that helps make cholesterol in the body. It also causes an increase in the breakdown of cholesterol. The information gained from this study may help doctors learn more about atorvastatin as an agent in cancer prevention, and may help to improve public health.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVE:

I. To determine the effect of atorvastatin calcium (atorvastatin) treatment on reducing the fraction of colonic epithelial cells expressing mutant p53 protein detected via immunohistochemical staining in biopsy samples of colorectal mucosa obtained during colonoscopies done before and after atorvastatin intervention and compared to placebo control.

SECONDARY OBJECTIVES:

I. Examination of the effect of atorvastatin on the levels of biomarkers including Ki-67 (cell proliferation), Waf1p21 (wild type p53 allele reactivated signal), and cleaved caspase-3 (wild type p53-induced cell apoptosis) using immunohistochemistry (IHC) approach for colorectal biopsy specimens.

II. Examination of the effect of atorvastatin on the severity of histologic inflammation in colorectal biopsies using the Geboes grading system.

III. Examination of the effect of atorvastatin on the plasma concentration of cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) for monitoring atorvastatin effect on lowering cholesterol and its correlation with the levels of biomarkers in the colorectal biopsies.

IV. Examination of the effect of atorvastatin on the clinical efficacy on ulcerative colitis (UC) related symptoms using the Ulcerative Colitis Disease Activity Index (i.e. the Mayo score).

EXPLORATORY OBJECTIVES I. Examination of the effect of atorvastatin on the spectrum, hotspot and load of TP53 gene mutations using next generation sequencing and droplet digital polymerase chain reaction (PCR).

II. Will bank colorectal biopsies and blood samples and ribonucleic acid (RNA) and germline deoxyribonucleic acid (DNA) for future analyses, particularly on proteomics/prenylated protein profile, cytokine/chemokine profile, inflammatory lipid-mediator profile, RNA sequencing (RNAseq) and Chaperon/Co-chaperon proteins, etc.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive atorvastatin orally (PO) once daily (QD) for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.

ARM II: Patients receive placebo PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.

After completion of study treatment, patients are followed up at 2 weeks.

연구 유형

중재적

등록 (실제)

42

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participants must have ulcerative colitis with > 8 years history and clinical remission (including the clinical remission for an extraintestinal manifestation/complication) confirmed by yearly surveillance endoscopy examination (Mayo grading < 3)
  • They must be stable on maintenance therapy with mesalamine, thiopurines or biologics for over 3 months (Ulcerative Colitis Disease Activity Index [UCDAI] =< 1)
  • A history of segmental colon resection is allowed
  • UC in clinical remission, but with dysplasia-associated lesion or mass (DALM) at entry endoscope examination and DALM was completely resected by endoscopic mucosa resection, is allowed
  • Participants 18-70 years old (both men and women). This is the standard age range for routine ulcerative colitis surveillance in adults
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • White blood cell count within normal institutional limits or absolute neutrophil count >= 1,500/uL
  • Platelets >= 100,000/uL
  • Total bilirubin within normal institutional limits, unless known to have Gilberts syndrome
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (SGPT) =< 1.5 X institutional upper limit of normal (ULN)
  • Creatinine =< 1.5 X institutional ULN
  • Plasma level of cholesterol < 240 mg/dl or LDL-C < 190 mg/dl (since cholesterol > 240 mg/dl and LDL-C > 190 mg/dl need high dose (40 - 80 mg) atorvastatin per day to control hypercholesterolemia)
  • For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Participants on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
  • Atorvastatin is contraindicated in pregnancy since it affects cholesterol synthesis pathway. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of baseline pregnancy test, throughout the duration of the study, and for 1 month following cessation of study drug. Females must begin adequate contraception immediately following screening pregnancy test. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If she is pregnant, she will be immediately withdrawn from the study and followed until the birth of the child
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Ulcerative proctitis (since patients with ulcerative proctitis have a significantly lower risk of developing colorectal cancer [CRC] than those with pancolitis or localized UC in left colon)
  • Participants with medical conditions that, in the opinion of the investigator, would preclude the treatment intervention and colonoscopy, or limit ability to comply with therapy
  • Participants with pancolitis or localized UC with total Mayo score >= 3 including Mayo endoscopic sub-score < 3 are excluded
  • Use of corticosteroid therapy in the past 3 months due to high potential of relapse of active disease
  • Use of statins in the last 12 months
  • Use of any investigational drugs within the past 3 months
  • A history of high-grade dysplasia or CRC or pan/severe colitis with total proctocolectomy
  • History of chemotherapy within 2 years of screening
  • History of allergic reactions attributed to atorvastatin
  • Concomitant primary sclerosing cholangitis (PSC) with stage 4 liver fibrosis (biliary cirrhosis) and severe liver functional alteration
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or breastfeeding participants are excluded
  • Human immunodeficiency virus (HIV)-positive participants are excluded due to anti-retroviral therapy that affect atorvastatin effect
  • Children are excluded from this study since disease duration is usually < 8 years and there is no data about p53 mutation in this patient population
  • Current use of cyclosporine, fibrates (e.g., gemfibrozil, fenofibrate), strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, human immunodeficiency virus (HIV) protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, or cobicistat-containing products), or strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort, bosentan, efavirenz, etravirine, modafinil, nafcillin)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I (atorvastatin, biospecimen collection)

Patients receive atorvastatin PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.

Ancillary studies

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Given PO

다른 이름들:
  • 리피토
  • CI-981
  • 아토르바스타틴 칼슘 트리하이드레이트

Undergo colonoscopy with biopsy

다른 이름들:
  • 대장내시경 생검
  • 대장내시경 및 생검
위약 비교기: Arm II (placebo, biospecimen collection)

Patients receive placebo PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.

Ancillary studies

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Given PO

Undergo colonoscopy with biopsy

다른 이름들:
  • 대장내시경 생검
  • 대장내시경 및 생검

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention
기간: Up to 2 years

Counted as p53 positive cells/100 epithelial cells under at least 5 high powered fields per slide or 100 crypts or 2000 cells/slide per biopsy, measured by immunohistochemistry (IHC) staining. The level of biomarker expression will be determined by chromogenic staining. Because multiple samples will be obtained per participant, participant-level %p53 mutation will be summarized as the average %p53 across these samples. Descriptive statistics will be used to summarize changes in each arm, as well as the difference in change between arms. Analysis will be conducted using a two-sample t-test comparing within-subject changes in average percentage (%) p53 between treatment arms. A more comprehensive analysis will be done using a linear mixed effects model, where the outcome variable will be %p53 staining in each sample evaluated at baseline and post-treatment.

Up to 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Levels of biomarkers of Ki-67 (cell proliferation), Waf1p21 (wild type p53 allele reactivated signal), and cleaved caspase-3 (wild type p53-induced cell apoptosis)
기간: Up to 2 years

Using IHC approach for colorectal biopsy specimens.

Up to 2 years
Histological analysis for grading the severity of histologic inflammation in colorectal biopsies
기간: Up to 2 years

Using the Geboes grading system (grading score: 0 - 4). Highest grade histology and extent of UC (pancolitis vs localized UC) across multiple samples will be used at each time point. Changes in scores from baseline to post-treatment will be calculated, and compared between arms using the Wilcoxon rank sum test.

Up to 2 years
Plasma concentration of cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL)
기간: Up to 2 years

Will monitor atorvastatin effect on lowering cholesterol and its correlation with the levels of biomarkers in the colorectal biopsies. Changes in plasma concentration of cholesterol, HDL and LDL (for monitoring atorvastatin effect on lowering cholesterol) will be compared between treatment arms using similar approaches as the primary analysis of %TP53 described above. The association of plasma concentration of cholesterol, HDL and LDL with the levels of biomarkers in the colorectal biopsies will be analyzed using linear mixed models as described above with plasma level added to the model as a fixed effect. Separate models will be fitted for each type of cholesterol (total, HDL and LDL).

Up to 2 years
Clinical efficacy on UC related symptoms
기간: Up to 2 years

Using the Ulcerative Colitis Disease Activity Index (activity score: 0 - 4) (i.e. the Mayo score).

Up to 2 years

기타 결과 측정

결과 측정
측정값 설명
기간
Analysis of spectrum, hotspot and load of TP53 gene mutations
기간: Up to 2 years

Using next generation sequencing and droplet digital polymerase chain reaction (PCR) technologies. The spectrum of TP53 mutations will be analyzed for frequency of each hotspot mutation in each group. For analyzing binary variables (presence or absence of each hot spot mutation), a Pearson's chi-squared test will be used. Frequency of each hotspot mutation for each noted group will be provided as descriptive measures of location and variance. The load of TP53 mutations in the biopsy specimens will be quantified as the ratio of mutant allele to wild-type allele using droplet digital PCR and allele-specific primers. Descriptive statistics will be used to summarize these at each time point for each treatment arm. Changes in TP53 mutation load, a continuous biomarker, will be compared between treatment arms using similar approaches as the primary analysis of %TP53 described above.

Up to 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 의자: Stephen B Hanauer, MD, Northwestern University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 9월 24일

기본 완료 (실제)

2025년 12월 4일

연구 완료 (추정된)

2027년 5월 1일

연구 등록 날짜

최초 제출

2021년 2월 23일

QC 기준을 충족하는 최초 제출

2021년 2월 23일

처음 게시됨 (실제)

2021년 2월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI 20-02-02
  • P30CA060553 (미국 NIH 보조금/계약)
  • UG1CA242643 (미국 NIH 보조금/계약)
  • NCI-2021-01261 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • NCI20-02-02 (기타 식별자: Northwestern University)
  • NWU20-02-02 (기타 식별자: DCP)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .